SOHO Annual Meeting

The combination of selinexor and dexamethasone induced an overall response rate of 26.2% and a median overall survival of 8.6 months in patients with penta-refractory multiple myeloma, according to phase IIb results presented at the 2018 SOHO Annual Meeting.

In a presentation during the 2018 SOHO Annual Meeting, Simon Rule, MD, PhD, discusses the treatment of newly-diagnosed patients with MCL, emphasizing the benefits of the watch-and-wait approach.

Despite decades of drug development and a deepening understanding of the biology of diffuse large B-cell lymphoma, physicians haven’t seen much improvement in cure rates, Thomas E. Witzig, MD, said during a presentation at the 2018 SOHO Annual Meeting.

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses thrombotic risk for patients with essential thrombocythemia and polycythemia vera.

Consistent benefit was seen with carfilzomib (Kyprolis)-based regimens across subgroups of patients with multiple myeloma in the ASPIRE and ENDEAVOR trials, according to updated safety data reported at the 2018 SOHO Annual Meeting.

Adding the combination of venetoclax (Venclexta) and navitoclax (ABT-263) to chemotherapy induced an objective response rate of 66.7% in adults with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma, according to results from a small phase I study presented at the 2018 SOHO Annual Meeting.

In a presentation during the 2018 SOHO Annual Meeting, Terry J. Fry, MD, discussed some of the data that have been seen so far with CD19- and CD22-direct CAR T cells, and addressed resistance to these products.  

Predisposition to forms of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in pediatric patients can be caused by either classical inherited bone marrow failure syndromes or recently discovered genetic predisposition syndrome with autosomal dominant inheritance, Marcin Wlodarski, MD, explained.

Abdulraheem Yacoub, MD, associate professor of Hematology at the University of Kansas Cancer Center, discusses treatment beyond hydroxyurea in patients with polycythemia vera.<br /> &nbsp;

The adoption of intensive pediatric treatment regimens has resulted in improved survival for adolescents and young adults with acute lymphoblastic leukemia over the past decade, said Wendy Stock, MD, at the 2018 SOHO Annual Meeting.

Hydroxyurea has been the primary treatment for polycythemia vera for decades and it works for the majority of patients, said Abdulraheem Yacoub, MD. However, there is a subset of patients who develop resistance or intolerance to hydroxyurea, and investigators are working to find a solution for those patients.

Ruxolitinib (Jakafi) is the only FDA-approved agent for the treatment of patients with myelofibrosis, making resistance to this agent a particularly difficult treatment challenge. Combinations with ruxolitinib may reinvigorate the impact of the JAK inhibitor in relapsed, progressive, or intolerant patients, explained Robyn M. Scherber, MD, MPH, in a presentation at the 2018 SOHO Annual Meeting.

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, addresses the management of patients with myelofibrosis after failure on ruxolitinib (Jakafi).<br /> &nbsp;

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses using MRD to guide therapy in acute myeloid leukemia (AML).

Advancements made in the field of molecular genetics for patients with myeloproliferative neoplasms may be increasingly incorporated into treatment decisions, according to a presentation by Ann Mullally, MD, during the 2017 SOHO Annual Meeting.

Initial results from a phase III trial indicated that patients with newly diagnosed chronic myeloid leukemia treated with bosutinib (Bosulif) achieved response faster than patients treated with imatinib (Gleevec).

The treatment of myelofibrosis has changed significantly in the past few years, largely due to the approval of ruxolitinib (Jakafi). Although it provides durable improvements, the JAK inhibitor may be even more effective in combination&mdash;as inhibition of JAK-STAT signaling has not shown to be curative.

Efforts to improve outcomes in pediatric acute lymphoblastic leukemia should follow leads provided by next-generation sequencing and appropriate use of minimal residual disease criteria, a pediatric hematologist said at the 2017 Society of Hematology Oncology Annual Meeting in Houston.

Robert Orlowski, MD, PhD,&nbsp;Florence Maude Thomas Cancer Research&nbsp;professor and chair, ad interim,&nbsp;Department of Lymphoma &amp; Myeloma&nbsp;at&nbsp;The University of Texas MD Anderson Cancer Center, discusses remaining questions with multiple myeloma treatment.

Updated findings from the registration trial of the first FDA-approved CAR T-cell therapy showed that 83% of patients with acute lymphoblastic lymphoma achieved complete remission with complete or incomplete hematologic recovery, as reported at the 2017 Society of Hematologic Oncology Annual Meeting.<br /> &nbsp;

Guillermo Garcia-Manero, MD, discusses&nbsp;the potential impact of harnessing immunotherapeutics in MDS.

Marco Davila, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses MDS as an immunoresponsive disease and applying immunotherapies to MDS.

With a number of effective targeted therapies now available for patients with myeloproliferative neoplasms and chronic myeloid leukemia, patient selection for transplantation should rely heavily on prognostic scoring.

When it comes to managing high-risk patients with essential thrombocythemia (ET) or polycythemia vera (PV), John Mascarenhas, MD, starts with risk stratification.

Zeev Estrov, MD, professor of medicine, MD Anderson Cancer Center, discusses questions that still need to be answered in the myelofibrosis field.

According to Ruben A. Mesa, MD, developing a treatment plan for myelofibrosis (MF) patients who fail ruxolitinib requires an understanding of both current treatment options and those that are expected to become available within the next several years.

Zeev Estrov, MD, professor of medicine, MD Anderson Cancer Center, discusses the next steps in myelofibrosis research.

Immunotherapy offers promise in acute myeloid leukemia (AML), a disease type which has not seen significant progress in many years, said Naval G. Daver, MD, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Individualized treatment for Waldenstr&ouml;m&#39;s macroglobulinemia (WM) has become a feasible strategy with&nbsp;improved understanding of the disease and expanded treatment options.

As molecular and genetic studies have provided new insights into myelodysplastic and myeloproliferative neoplasms (MDS/MPN),&nbsp;diagnostic criteria and therapeutic strategies for the diseases continue to evolve.